Lactose in the Treatment of Intestinal Dysfunction in Moderately Severe Acute Pancreatitis: a Randomized Controlled Clinical Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027493

Enrollment

Unknown

Registered

2019-11-15

Start date

2019-11-20

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate Severe Acute Pancreatitis

Interventions

Group A:On the basis of routine treatment of acute pancreatitis, lactofructose was added, 50ml qd and jiexi15ml qd in the first 3 days

Group B:Acute pancreatitis comprehensive treatment, when necessary with glycerin enema laxation

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. MSAP patients within 1 week of onset; 2. Age between 18-70 years old; 3. There was gastrointestinal function damage (score > 0); 4. Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1. Complicated with gastrointestinal bleeding; 2. Combined with gastrointestinal fistula; 3. Combined intestinal obstruction; 4. Pregnant and lactating women; 5. Complicated gastrointestinal tumors, IBD; 6. Use other probiotics or probiotics.

Design outcomes

Primary

Measure	Time frame
Improvement degree of gastrointestinal function injury score;Analysis of intestinal flora and its metabolites SCFAs;Indicators of intestinal barrier injury;Inflammatory cytokines;	—

Secondary

Measure	Time frame
Enteral nutritional tolerance;WTO classification of abdominal pain;Defecation grading;Complications and outcomes;	—

Countries

China

Contacts

Public ContactNonghua Lyu

The First Affiliated Hospital of Nanchang University

lunonghua@163.com+86 13707086809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026